摘要
癫痫是一种常见的脑部疾病,由大脑神经元的反复异常放电引起。尽管目前有很多种抗癫痫药物可用,但是约30%的患者存在抗药性或者用药过程中出现了严重的不良反应。醋酸艾司利卡西平是卡马西平的衍生物,由Sunovion Pharmaceuticals Inc.公司研究开发,用于伴有或不伴有继发性全身发作的成人癫痫部分性发作的治疗。它是一种新型电压门控钠通道抑制剂,通过阻断动作电位的传导,以抑制脑神经元的反复异常放电,控制癫痫发作。本文对其作用机制、药动学、药效动力学、临床研究、安全性评价等做一介绍。
Epilepsy is a common neurological disorder caused by recurrent abnormal discharge of neurons in the brain. Although there are many antiepileptic drugs available, 30% of the patients present resistance to those drugs or show serious adverse reactions. Eslicarbazepine acetate (ESL) is one derivative of carbamazepine. It was developed by Sunovion Pharmaceuticals Inc. for treatment of adult epilepsy partial-onset seizures, with or without secondary generalized seizures. ESL is a novel voltage-gated sodium channel inhibitor, it restrains the abnormal discharge by cutting the conduction of nerve action potential, thus controls the epilepsy seizures. This paper summarized the mechanism, pharmacokinetics, pharmacodynamics, clinical trials, and safety assessments of ESL.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2014年第21期2461-2464,共4页
Chinese Journal of New Drugs